MedImmune Discontinues Rheumatoid Arthritis and Psoriasis Trials for Vitaxin(R)
Monday August 30, 9:05 am ET
Oncology Programs for Development-Stage Monoclonal Antibody Continue
GAITHERSBURG, Md., Aug. 30 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI - News) announced today that it has decided to terminate Phase 2 testing of Vitaxin® in patients with rheumatoid arthritis (RA) and psoriasis based on preliminary data suggesting lack of clinical benefit in these inflammatory diseases. There were no safety concerns identified in the preliminary analyses. MedImmune's oncology program for Vitaxin continues to advance with studies in melanoma and prostate cancer.
About Vitaxin
Vitaxin targets the alpha-v beta-3 integrin, which is a protein expressed on the surface of newly forming blood vessels, certain tumor types and on a number of other cell types, including macrophages and osteoclasts. Based on preclinical models, the alpha-v beta-3 integrin has been implicated in a number of disease processes, including the growth and metastasis of tumors, the bone destruction in RA and the inflammatory process in psoriasis... |
